Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
Immunic announced a virtual R&D Day focused on progressive multiple sclerosis, scheduled for November 5, 2026, at 12:30 pm ET. Management plans to highlight the expansion opportunity for lead asset vidofludimus calcium (IMU-838) in progressive MS, including plans to initiate a Phase 3 progressive MS trial later in 2026.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.